	US 12,226,484 B2
	Compositions having improved bioavailability of therapeutics
John Brew, St. Albans (GB); Daniel Gooding, Cambridge (GB); and Robin M. Bannister, Saffron Walden (GB)
Assigned to TRx Biosciences Limited, London (GB)
Filed by TRx Biosciences Limited, London (GB)
Filed on Oct. 16, 2023, as Appl. No. 18/487,486.
Application 18/487,486 is a continuation of application No. 17/656,702, filed on Mar. 28, 2022.
Claims priority of provisional application 63/269,330, filed on Mar. 14, 2022.
Claims priority of provisional application 63/166,995, filed on Mar. 27, 2021.
Prior Publication US 2024/0075147 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/14 (2017.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/216 (2006.01); A61K 31/4025 (2006.01); A61K 31/4184 (2006.01); A61K 31/436 (2006.01); A61K 31/44 (2006.01); A61K 31/4418 (2006.01); A61K 31/4453 (2006.01); A61K 31/496 (2006.01); A61K 31/502 (2006.01); A61K 31/5377 (2006.01); A61K 31/553 (2006.01); A61K 31/58 (2006.01); A61K 31/7135 (2006.01); A61K 38/12 (2006.01); A61K 47/28 (2006.01)

CPC A61K 47/14 (2013.01) [A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/216 (2013.01); A61K 31/4025 (2013.01); A61K 31/4184 (2013.01); A61K 31/436 (2013.01); A61K 31/44 (2013.01); A61K 31/4418 (2013.01); A61K 31/4453 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 31/58 (2013.01); A61K 31/7135 (2013.01); A61K 38/12 (2013.01); A61K 47/28 (2013.01)]

22 Claims

1. A pharmaceutical composition comprising:

a) one or more therapeutic compounds,

b) about 40% to about 80% by weight of the pharmaceutical composition of one or more glycerolipids, the one or more glycerolipids are one or more saturated C₁₀-C₂₂triglycerides and a mixture of unsaturated C₁₄-C₂₂monoglycerides, unsaturated C₁₄-C₂₂diglycerides, and unsaturated C₁₄-C₂₂triglycerides,

c) at least 5% to at most 50% by weight of the pharmaceutical composition of one or more free C₁₄-C₂₂fatty acids, and

d) about 0.5% to about 5.0% by weight of the pharmaceutical composition of one or more bile acids and/or one or more bile salts,

wherein the pharmaceutical composition is an anhydrous formulation, and

wherein the pharmaceutical composition is not an emulsion.